Phase II Study of Abiraterone Acetate Plus Prednisone in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Demonstrating Radiographic Flare Discordant With Serologic Measures of Response

PURPOSE: Abiraterone is an oral inhibitor of CYP17, essential for androgen biosynthesis. This multicenter study assessed its efficacy in patients with CRPC without prior exposure to chemotherapy or CYP17 targeted therapy, and assessed the frequency of interpretation of bone scans discordant with PSA...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Ryan, Charles J., Shah, Shreya, Efstathiou, Eleni, Smith, Matthew R., Taplin, Mary-Ellen, Bubley, Glenn J., Logothetis, Christopher J., Kheoh, Thian, Kilian, Christine, Haqq, Chris, Molina, Arturo, Small, Eric J.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2011
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3657705/
https://ncbi.nlm.nih.gov/pubmed/21632851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-0815
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk